Antares Pharma, INC.: insider trades · United States · SEC (Form 4)

About Antares Pharma, INC.

Antares Pharma, Inc. was a U.S.-based specialty pharmaceutical and drug-delivery company historically traded on NASDAQ under the ticker ATRS, with principal executive offices in Ewing, New Jersey, United States. The company built its identity around self-administered injectable therapies and combination products that pair a drug with an advanced delivery device. Its core business model centered on developing, commercializing, and, in some cases, partnering on injectable pharmaceutical products that are designed to improve convenience, adherence, and patient self-administration. Founded in the late 1990s, Antares evolved into what management repeatedly described as a pharmaceutical technology company focused on parenteral and subcutaneous delivery. Over time, it assembled a portfolio spanning proprietary and partnered products, generating revenue from commercial sales as well as collaboration and licensing structures. Among its best-known offerings were XYOSTED, a subcutaneous testosterone enanthate auto-injector for testosterone replacement therapy, and OTREXUP, a ready-to-use methotrexate injection for selected rheumatology and dermatology indications. The company also developed device platforms and supported partner programs in areas such as allergy, women’s health, and other niche injectable categories. From a competitive standpoint, Antares occupied a focused niche rather than competing head-on with large diversified pharmaceutical companies. Its differentiation lay in drug-delivery engineering, especially auto-injector technology designed to make injectable treatments easier, safer, and more patient-friendly. That positioning was relevant in markets where convenience, dosing consistency, and at-home administration can be important adoption drivers. The company also maintained research and development activity beyond New Jersey, including a presence in Minnesota, reflecting its mix of pharmaceutical and device expertise. Recent corporate history is dominated by consolidation. Antares was acquired by Halozyme, with the transaction completed in May 2022, so ATRS no longer operates as an independent publicly listed issuer. Prior to that acquisition, the company had achieved key regulatory and commercial milestones, most notably the FDA approval and launch of XYOSTED, while also streamlining its portfolio through asset dispositions such as the divestiture of OTREXUP. For investors, Antares is best understood as a specialized U.S. NASDAQ healthcare platform that was ultimately folded into a larger drug-delivery and specialty pharma group through industry consolidation.